Catalyst
Slingshot members are tracking this event:
Incyte (INCY) and Merck (MRK) Present Updated Results on Phase 1 ECHO-202 Trial Evaluating Epacadostat + Keytruda in Treatment-Naive Advanced/Metastatic Melanoma Patients
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 07, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 1, Echo-202, Epacadostat, Keytruda, Treatment-naive Advanced/metastatic Melanoma, European Society For Medical Oncology
